- Home
- PRHI vs BIVI Comparison
PRHI vs BIVI Comparison
Compare PRHI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | BIVI |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRHI | BIVI |
|---|---|---|
| Price | $0.59 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.9K | ★ 65.0K |
| Earning Date | 03-09-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.62 |
| 52 Week High | $2.83 | $9.09 |
Technical Indicators
Market Signals| Indicator | PRHI | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 55.45 |
| Support Level | $0.53 | $1.07 |
| Resistance Level | $0.87 | $1.68 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 6.07 | 57.41 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.